Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Clinical trial NCT07557914 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07557914
- Sponsor
- Haibo Shao
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2029-02-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.